Quince Therapeutics, Inc. (IRLA): Total Assets
$93.52M
As of 2025-12-31
$124.00M
As of 2026-06-30
-3.4%
3-year compound annual growth
-13.2%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.52M | -18.3% | 2026-04-10, Balance as of period end |
| 2024-12-31 | $114.48M | -31.8% | 2026-04-10, Balance as of period end |
| 2023-12-31 | $167.90M | +61.6% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $103.91M | -22.0% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $133.23M | -29.7% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $189.47M | +52.3% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $124.37M | +70.7% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $72.88M | n/a | 2020-03-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (IRLA) | 2025-12-31 | $93.52M | -18.3% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $93.00M | -4.0% |
| LeonaBio, Inc. (LONA) | 2025-12-31 | $92.15M | +56.8% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $98.73M | +103.7% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $88.53M | +26.3% |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | $103.81M | -23.4% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $82.35M | +12.2% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $79.73M | +57.1% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
Compare IRLA, ATYR, LONA, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗